Doppler-defined pulmonary hypertension in sepsis and septic shock
The authors of this study state that the association of pulmonary hypertension (PH) in patients with sepsis is lesser understood. In patients with sepsis and septic shock, PH is common and is noted to be associated with higher short and long-term mortality. Further studies are needed to understand the mechanisms by which PH is associated with outcomes. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 17, 2019 Category: Consumer Health News Source Type: news

What Are Potential Complications of Large for Gestational Birthweight?
Discussion Infant size at birth is determined mainly by genetics, but also pregnancy and environmental factors. Large for gestational age (LGA) is defined as a mean weight> 2 standard deviations above the weight for gestational age or above the 90th percentile on growth charts (or ~4000 g on WHO growth charts). Macrosomia is a term used for a term infant who is> 4000g. Risk factors for LGA infants includes: Male infant Maternal Genetic disposition Hispanic ethnicity Diabetic Multiparity or grand parity Obesity History of previous LGA infant Prenatal ultrasound is very helpful for antenatal management. First tri...
Source: PediatricEducation.org - January 14, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Blood pressure science paper in a pharmacology journal RETRACTED after data manipulation discovered
(Natural News) A 2011 paper published in the British Journal of Pharmacology (BJP) has been retracted after it was found that data represented in the study was manipulated. The paper, entitled, “Mice lacking the Raf-1 kinase inhibitor protein exhibit exaggerated hypoxia-induced pulmonary hypertension,” documented a study that concluded that a specific protein (which regulates various... (Source: NaturalNews.com)
Source: NaturalNews.com - January 10, 2019 Category: Consumer Health News Source Type: news

Treprostinil Boosts Exercise Capacity in Severe Thromboembolic Pulmonary HTN Treprostinil Boosts Exercise Capacity in Severe Thromboembolic Pulmonary HTN
Subcutaneous treprostinil appears safe and improves exercise capacity in patients with severe non-operable chronic thromboembolic pulmonary hypertension (CTEPH), according to results from a phase 3 randomized controlled trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 2, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

FDA grants breakthrough status to joint Merck-Bayer AI program
Merck and Bayer have been granted FDA Breakthrough Device Designation for the collaborative Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Artificial Intelligence Pattern Recognition software. CTEPH can be difficult to diagnose because its symptoms are similar to asthma and chronic obstructive pulmonary disease symptoms. CTEPH affects five people per million annually worldwide. Computed tomography pulmonary angiography and a ventilation/perfusion scan can be used to determine if thromboembolic occlusion is causing pulmonary hypertension in patients. Get the full story on our sister site, Medical Design & Outsour...
Source: Mass Device - December 10, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: Food & Drug Administration (FDA) Bayer Merck Source Type: news

Large Companies Eye Collaboration as Entry into AI
Edwards Lifesciences is delving deeper into the realm of artificial intelligence through a partnership with San Francisco-based Bay Labs. The goal of the collaboration, which has multiple initiatives is to improve the detection of heart disease. Some of the initiatives include, the development of new AI-powered algorithms in Bay Labs’ EchoMD measurement and interpretation software suite; support for ongoing clinical studies at institutions; and the integration of EchoMD algorithms into Edwards Lifesciences’ CardioCare quality care navigation platform. Irvine, CA-based Edwardsâ€...
Source: MDDI - December 10, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news

Drug Maker Pays $360 Million to Settle Investigation Into Charity Kickbacks
Prosecutors accused Actelion Pharmaceuticals, which Johnson& Johnson acquired in 2017, of violating Medicare laws by funneling money through a patient-assistance charity. (Source: NYT Health)
Source: NYT Health - December 6, 2018 Category: Consumer Health News Authors: KATIE THOMAS Tags: Drugs (Pharmaceuticals) Prices (Fares, Fees and Rates) Actelion Pharmaceuticals Ltd Johnson & United Therapeutics Corporation Medicare Bribery and Kickbacks Pulmonary Hypertension Justice Department Health Insurance and Managed Care Source Type: news

FDA grants special designation for Bayer AI software
Bayer announced in a release that the U.S. Food and Drug Administration granted a breakthrough device designation for an AI pattern recognition software that it is jointly developing with Merck. The software is designed for the treatment of chronic thromboembolic Pulmonary Hypertension (CTEPH), a rare form of pulmonary hypertension that is often difficult to diagnose because symptoms often mimic those of asthma or chronic obstructive pulmonary disease (COPD). Working together, Bayer and Merck have… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 4, 2018 Category: Health Management Authors: Mike Larson Source Type: news

FDA Grants Breakthrough Device Designation to Artificial Intelligence Software for CTEPH Pattern Recognition from Bayer and MSD
Bayer announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Pattern Recognition, which Bayer is currently developing jointly with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA). (Source: eHealth News EU)
Source: eHealth News EU - December 4, 2018 Category: Information Technology Tags: Featured Industry Business and Industry Source Type: news

FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD
Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Pattern Recognition, which Bayer is currently developing jointly with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA). (Source: World Pharma News)
Source: World Pharma News - December 3, 2018 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD
The software in development intends to support clinical decision-making of chronic thromboembolic pulmonary hypertension– a progressive and life-threatening condition (Source: Bayer Company News)
Source: Bayer Company News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Protein central to immune system function new target for treating pulmonary hypertension
(Virginia Commonwealth University) A protein with a role in sensing cell damage and viral infections is a new target for the treatment of pulmonary hypertension, or increased blood pressure in the lungs, according to research led by Virginia Commonwealth University and the University of Sheffield in the United Kingdom. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 15, 2018 Category: International Medicine & Public Health Source Type: news

Influence of Anemia on One-Year Exacerbation Rate of COPD-PH Influence of Anemia on One-Year Exacerbation Rate of COPD-PH
A new study explores the potential prognostic role of anemia in patients with pulmonary hypertension due to COPD.BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 16, 2018 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

PADN-5: Ablation Reduces Pulmonary Hypertension in HF PADN-5: Ablation Reduces Pulmonary Hypertension in HF
Pulmonary artery denervation improved hemodynamic and clinical outcomes at 6 months, but design flaws in the sham-controlled study may muddy the results, a clinical trials expert cautions.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 24, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

United Therapeutics And MannKind Announce Collaboration For Pulmonary Hypertension Products
Exclusive license agreement for Treprostinil Technosphere®; $95 million in upfront and milestone payments Research agreement for additional products for additional $10 million SILVER SPRING, Md. and WESTLAKE VILLAGE, Calif., Sept. 4, 2018 -- (Hea... Biopharmaceuticals, Licensing United Therapeutics, MannKind, Treprostinil, Technosphere (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 4, 2018 Category: Pharmaceuticals Source Type: news

Deadly Respiratory Distress Mimic
Conclusion It’s important for prehospital providers to be able to differentiate metabolic disturbances in the setting of respiratory distress and not be fooled into thinking tachypnea always has a respiratory cause. The physical exam and adjuncts such as end-tidal capnography can assist in the prehospital diagnosis. A COPD exacerbation generally presents as diminished lung sounds, wheezing on exhalation, and a prolonged expiratory phase. Here, a patient will attempt to compensate for the inflammation and mucus accumulation associated with the destruction and narrowing of peripheral airways and a subsequent lack of av...
Source: JEMS Special Topics - July 17, 2018 Category: Emergency Medicine Authors: Brenton Faber, PhD, NRP Tags: Airway & Respiratory Exclusive Articles Patient Care Source Type: news

SPONSORED: Handy Help For The Heart
Knowledge of symptoms and available treatments are key to fighting atrial fibrillation and pulmonary hypertension. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - June 20, 2018 Category: American Health Source Type: news

New pulmonary hypertension treatment target in the bull's-eye
(Medical College of Georgia at Augusta University) A new and early target for treating pulmonary hypertension appears to be an enzyme that's normally key to energy production but destructive in the face of this high blood pressure inside your lungs. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 8, 2018 Category: Biology Source Type: news

Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT ® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 30, 2018 Category: Pharmaceuticals Source Type: news

Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT(R) (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Filing supported by data from MERIT-1 trial evaluating OPSUMIT in adults with inoperable CTEPH which showed significant improvements in pulmonary vascular resistance and six-minute walk distance (6MWD) compared with ongoing background therapy CHERRY HIL... Biopharmaceuticals, FDA Actelion Pharmaceuticals, Janssen, Johnson & Johnson, OPSUMIT, macitentan (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2018 Category: Pharmaceuticals Source Type: news

Study identifies new target for treatment of pulmonary hypertension
(Ann& Robert H. Lurie Children's Hospital of Chicago) Inhibiting FoxM1 gene reverses disease process in animal models of pulmonary hypertension. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 30, 2018 Category: International Medicine & Public Health Source Type: news

Crosstalk between cells plays role in pulmonary hypertension
Molecular signals between specialized cells in the lungs and arteries may be responsible for high blood pressure in the lungs, according to new research. (Source: Yale Science and Health News)
Source: Yale Science and Health News - April 24, 2018 Category: Universities & Medical Training Source Type: news

Pulmonary Hypertension: Not Just for Cardiologists
(MedPage Today) -- PH is common in many rheumatologic conditions (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 19, 2018 Category: Cardiology Source Type: news

Genes isolated for pulmonary arterial hypertension
Doctors hope the discovery will lead to potential new treatments Related items fromOnMedica Antidepressant link to persistent pulmonary hypertension NHS funds pioneering lung procedure Researchers identify gene for irregular heartbeat Scientists find new markers for high blood pressure UK mass gene sequencing breakthrough (Source: OnMedica Latest News)
Source: OnMedica Latest News - April 16, 2018 Category: UK Health Source Type: news

Pregnancy Outcome in a Pregnant Patient With Idiopathic PAH Pregnancy Outcome in a Pregnant Patient With Idiopathic PAH
While the risk of mortality in pregnant patients with idiopathic pulmonary hypertension remains high, this case demonstrates that with proper care it is possible for these patients to carry to term.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 13, 2018 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news

Hemodynamic Parameters Predict Outcome in PH - HFpEF
Tied to mortality, hospitalization in pulmonary hypertension in HF with preserved ejection fraction (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 16, 2018 Category: Respiratory Medicine Tags: Cardiology, Internal Medicine, Pulmonology, Journal, Source Type: news

HFpEF With Pulmonary Vascular Disease: A New Phenotype? HFpEF With Pulmonary Vascular Disease: A New Phenotype?
What do we know about the emerging clinical syndrome of pulmonary hypertension in HFpEF, and what do we still need to learn? This brief summarizes current knowledge of this newly recognized problem.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 8, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Boston Children ’ s, Boston Pediatric Device Consortium announces device challenge winners
The Boston Pediatric Device Strategic Partner Challenge recently announced its winners, including cardiovascular devices that expand to keep pace with growing child, a nitric oxide generator, a cardiovascular diagnostic device and other novel pediatric devices. The challenge, run by the Innovation and Digital Health Accelerator at Boston Children’s Hospital and the Boston Pediatric Device Consortium, announced a total of five winners for the challenge. Winners will receive a combination of up to $50,000 in funding per grant award and possible mentorship programs with medical device strategic partners, including Bosto...
Source: Mass Device - January 25, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Research & Development Boston Children's Hospital Boston Scientific CryoLife Edwards Lifesciences johnsonandjohnson Medtronic Ximedica LLC Source Type: news

Doctors who order fewer CTPA scans detect more PE
Turns out that less really is more. Canadian researchers are reporting that...Read more on AuntMinnie.comRelated Reading: Ultrasound elevates diagnosis of pulmonary embolism ACP: Routine CT for suspected PE is unnecessary CTPA-based prediction model nails pulmonary hypertension ARRS: Pulmonary MRI feasible for evaluating acute PE CAD may catch missed pulmonary embolism on CTPA studies (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 8, 2018 Category: Radiology Source Type: news

Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial
Bellerophon Therapeutics (NSDQ:BLPH) has enrolled the first patient in a Phase IIb study assessing its INOpulse device in patients with pulmonary hypertension due to interstitial lung disease. The company’s placebo-controlled study is slated to evaluate the safety and efficacy of pulsed, inhaled nitric oxide in patients with PH-ILD, including those with idiopathic pulmonary fibrosis, Bellerophon reported. Get the full story at out sister site, Drug Delivery Business News. The post Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 4, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Bellerophon Therapeutics Source Type: news

Pulmonary Hypertension Treatment and Research
(Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - December 12, 2017 Category: Consumer Health News Source Type: news

Genes on Y chromosome protect against pulmonary hypertension, study suggests
This study is the first to examine the involvement of sex chromosomes in the disease's development in the absence of sex hormones. In humans, females typically have two copies of the X chromosome, while males typically have one X and one Y chromosome.METHODIn the lab, the researchers engineered mice with different chromosomal makeups and measured their development of pulmonary hypertension in an environment with 10 percent oxygen, which is a well-established setting for inducing the disease.One group of mice was engineered with sex chromosomes that were independent of their gonadal sex, or sex based on their genitalia, so ...
Source: UCLA Newsroom: Health Sciences - December 4, 2017 Category: Universities & Medical Training Source Type: news

Critical Care Management of Pulmonary Hypertension Critical Care Management of Pulmonary Hypertension
How should patients with pulmonary hypertension in the critical care setting be approached? This overview highlights key points in diagnosis and management of this challenging disorder.BJA Education (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 28, 2017 Category: Intensive Care Tags: Critical Care Journal Article Source Type: news

Lung cancer triggers pulmonary hypertension
(Max-Planck-Gesellschaft) Nearly half of all advanced-stage lung cancer patients develop arterial pulmonary hypertension. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 22, 2017 Category: Cancer & Oncology Source Type: news

Papers of note in Science Translational Medicine 9 (416)
This week’s articles describe why pulmonary hypertension often arises with lung cancer; a way to interrupt the autoimmune response in type 1 diabetes; and a marker through which to screen patients for response to MSC therapy and risk for graft-versus-host disease. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - November 21, 2017 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news

Your NEJM Group Today: Button Magnets in Nasal Cavity / Borderline Pulmonary Hypertension & Mortality / New York FM Opportunities (FREE)
By the Editors Here's what we chose for you from NEJM Group today:NEJM Clinical Practice Center: Images in Clinical Medicine: An … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 30, 2017 Category: Primary Care Source Type: news

Borderline Pulmonary Hypertension Tied to Mortality Risk
(MedPage Today) -- Small increases in pressure might signal left heart failure, not early PAH (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 25, 2017 Category: Cardiology Source Type: news

Targeting mitochondria in pulmonary hypertension
(University of Alberta Faculty of Medicine& Dentistry) Investigators at the University of Alberta and the Imperial College of Medicine have shown that the generic drug, Dichloroacetate (DCA), can decrease the blood pressure in the lungs of pulmonary arterial hypertension patients and improve their ability to walk, without significant side effects at the doses tested. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 25, 2017 Category: Cancer & Oncology Source Type: news

United Therapeutics lands FDA approval linked to drug at center of patent lawsuits
United Therapeutics Corporation (Nasdaq: UTHR) – which is headquartered in Silver Spring, Maryland, and has an office in Research Triangle Park – has landed U.S. Food and Drug Administration approval for a new device to be used with one of its drugs currently at the center of a number of patent-related lawsuits.  The company received FDA a pproval for its pulmonary hypertension drug Tyvaso back in 2009, and its latest approval is for a new inhalation device – called TD-300/A – to be used… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 24, 2017 Category: American Health Authors: Jennifer Henderson Source Type: news

‘Zero Communication.’ Puerto Ricans Are Hunting for Wi-Fi and Cell Signal to Contact Loved Ones
(SAN JUAN, Puerto Rico) — Margarita Aponte and her relatives cleared the road in front of her house with two oxen Sunday, then drove an hour from her devastated hometown in central Puerto Rico to the old telegraph building in the capital of San Juan. There, thousands of Puerto Ricans gathered for a chance at a resource nearly as precious as power and water in the wake of Hurricane Maria — communication. “It’s ringing, it’s ringing, it’s ringing!” Aponte, a janitor, screamed as her phone connected to free Wi-Fi and her Facetime call went through to the mainland. Her eyes filled wit...
Source: TIME.com: Top Science and Health Stories - September 25, 2017 Category: Consumer Health News Authors: Danica Coto / AP Tags: Uncategorized Hurricane Maria onetime Puerto Rico Source Type: news

Pulmonary Hypertension in ARDS: Inflammation Matters! Pulmonary Hypertension in ARDS: Inflammation Matters!
This editorial discusses the significance of inflammation in the pathogenesis of pulmonary hypertension in acute respiratory distress syndrome.Thorax (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Bellerophon Therapeutics touts Ph2 COPD trial of inhaled nitric oxide
Bellerophon Therapeutics (NSDQ:BLPH) touted data today from a Phase II trial of pulsed, inhaled nitric oxide in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease. The 10-patient trial was designed to evaluate the effects of pulsed, inhaled nitric oxide on targeted vasodilation and the chronic effect on hemodynamics and exercise capacity. Get the full story at our sister site, Drug Delivery Business News. The post Bellerophon Therapeutics touts Ph2 COPD trial of inhaled nitric oxide appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 5, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat Bellerophon Therapeutics Source Type: news

Pulmonary hypertension cure? This could treat high blood pressure affecting LUNGS
PULMONARY arterial hypertension is caused by changes to the pulmonary arteries - the blood vessels that carry blood from the heart to the lungs. (Source: Daily Express - Health)
Source: Daily Express - Health - September 1, 2017 Category: Consumer Health News Source Type: news

Study: Viagra may harm, not help, patients with heart valve disorder
New research suggests Viagra (sildenafil) might raise patients' risk of " pulmonary hypertension linked to valvular heart disease. " (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 30, 2017 Category: Consumer Health News Source Type: news

Sildenafil Warning in Pulmonary Hypertension After Valve Surgery Sildenafil Warning in Pulmonary Hypertension After Valve Surgery
Clinicians should not assume that sildenafil is beneficial in pulmonary hypertension following valve surgery, warn Spanish researchers after finding the drug doubles clinical events in these patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 28, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Sildenafil should be avoided in valve disease with residual pulmonary hypertension
(European Society of Cardiology) Sildenafil should not be used to treat residual hypertension in patients with valvular heart disease, according to late-breaking results from the SIOVAC trial presented today in a Hot Line LBCT Session at ESC Congress. The off-label use of the drug led to worse clinical outcomes including a doubled risk of hospitalization compared to placebo. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 28, 2017 Category: International Medicine & Public Health Source Type: news

Ventripoint touts publication of VMS heart analysis system study
Ventripoint Diagnostics this week announced the publication of a study of its VMS heart analysis system, touting that the system’s functionality. The study, undertaken by the cardiology group at London’s Royal Free Hospital, was published in the journal Echocardiography. Results from the study indicate that the system was able to follow patients with enlarged right ventricles and accurately measure small but significant changes in volume and function, Ventripoint said. The company said that the system’s ability to monitor clinical outcomes after therapy has been initiated is important in determining if th...
Source: Mass Device - August 22, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials VentriPoint Diagnostics Source Type: news

At What Height Do You Consider Preventative Treatment for Acute Mountain Sickness?
Discussion Acute mountain sickness (AMS) is a well-known problem for some people who travel to high altitude, especially altitudes> 2500 m (~8200 feet). Symptoms include headache, nausea or emesis, shortness of breath, dizziness, fatigue, difficulty sleeping and poor appetite. The incidence in adults ranges from 25% at 2975 m to up to 75% at 5896 m. The incidence in children is less clear but it appears that children are more susceptible at 45% for 16-19 year olds for similar altitudes. Risk factors are numerous including age, gender, obesity, ascent rate, altitude for sleeping, previous exposure to high altitude, previ...
Source: PediatricEducation.org - August 21, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

FDA accepts Bellerophon ’s Phase IIb design for INOpulse in PH-ILD
The US Food and Drug Administration (FDA) has accepted Bellerophon Therapeutics ’ study design for the Phase IIb clinical trial of INOpulse in patients with Interstitial Lung Disease (ILD) associated pulmonary hypertension (PH). (Source: Drug Development Technology)
Source: Drug Development Technology - August 3, 2017 Category: Pharmaceuticals Source Type: news